[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

NO20075087L - Kombinasjoner, metoder og sammensetninger for behandling av cancer - Google Patents

Kombinasjoner, metoder og sammensetninger for behandling av cancer

Info

Publication number
NO20075087L
NO20075087L NO20075087A NO20075087A NO20075087L NO 20075087 L NO20075087 L NO 20075087L NO 20075087 A NO20075087 A NO 20075087A NO 20075087 A NO20075087 A NO 20075087A NO 20075087 L NO20075087 L NO 20075087L
Authority
NO
Norway
Prior art keywords
treatment
methods
cancer
compositions
combinations
Prior art date
Application number
NO20075087A
Other languages
English (en)
Inventor
Francis Y F Lee
Roberto Weinmann
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of NO20075087L publication Critical patent/NO20075087L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Oppfinnelsen angår en kombinasjon av BCR-ABL-inhibitor, eksemplifisert ved 'N-(2-klor-6-metylfenyl)-2-[[6-[4-(2-hydroksyetyl)-1-piperazinyl]-2-metyl-4-pyrimidinyl]amino]-5-tiazolkarboksamid og/eller andre BCR/ABL-inhibitorer og et stamcelle-selektivt cytotoksisk middel, eksemplifisert ved (R)-2,3,4,5-tetrahydro-1-(1H-imidazol-4-ylmetyl)-3-(fenylmetyl)-4-(2-tienylsulfonyl)-1H-1,4-benzodiazepin-7-karbonitril-hydrokloridsalt og eller andre stamcelle-cytotoksiske midler, farmasøytiske preparater av kombinasjonen og metoder for anvendelse av de farmasøytiske preparater ved behandling av onkologiske lidelser.
NO20075087A 2005-04-13 2007-10-09 Kombinasjoner, metoder og sammensetninger for behandling av cancer NO20075087L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US67074405P 2005-04-13 2005-04-13
US74843305P 2005-12-08 2005-12-08
US11/402,502 US20060235006A1 (en) 2005-04-13 2006-04-12 Combinations, methods and compositions for treating cancer
PCT/US2006/013773 WO2006113304A2 (en) 2005-04-13 2006-04-13 Combinations, methods and compositions for treating cancer

Publications (1)

Publication Number Publication Date
NO20075087L true NO20075087L (no) 2008-01-09

Family

ID=37109315

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20075087A NO20075087L (no) 2005-04-13 2007-10-09 Kombinasjoner, metoder og sammensetninger for behandling av cancer

Country Status (12)

Country Link
US (2) US20060235006A1 (no)
EP (1) EP1868435A4 (no)
JP (1) JP2008536853A (no)
KR (1) KR20080004495A (no)
AU (1) AU2006236812A1 (no)
BR (1) BRPI0608176A2 (no)
CA (1) CA2604581A1 (no)
EA (1) EA200702238A1 (no)
MX (1) MX2007012537A (no)
NO (1) NO20075087L (no)
TW (1) TW200722091A (no)
WO (1) WO2006113304A2 (no)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1348370A (zh) 1999-04-15 2002-05-08 布里斯托尔-迈尔斯斯奎布公司 环状蛋白酪氨酸激酶抑制剂
DE602006021142D1 (de) 2005-02-03 2011-05-19 Gen Hospital Corp Verfahren zur behandlung von gefitinib-resistentem krebs
US8247419B2 (en) * 2005-06-09 2012-08-21 Bristol-Myers Squibb Company Methods of identifying and treating individuals exhibiting mutant kit protein
RU2451524C2 (ru) 2005-11-04 2012-05-27 Вайет Противоопухолевые комбинации с ингибиторами mtor, герцептином и/или hki-272
US20090099197A1 (en) * 2005-11-15 2009-04-16 Bristol-Myers Squibb Company Methods of Identifying and Treating Individuals Exhibiting MDR-1 Overexpression With Protein Tyrosine Kinase Inhibitors and Combinations Thereof
CN102861338A (zh) * 2006-04-05 2013-01-09 诺瓦提斯公司 用于治疗癌症、包含bcr-abl/c-kit/pdgf-r tk抑制剂的组合
WO2007116025A2 (en) * 2006-04-07 2007-10-18 Novartis Ag Use of c-src inhibitors in combination with a pyrimidylaminobenzamide compound for the treatment of leukemia
WO2008064004A2 (en) * 2006-11-16 2008-05-29 Wyeth 4-anilino-3-quinolinecarbonitriles for the treatment of acute myelogenous leukemia (aml)
US20080119463A1 (en) * 2006-11-16 2008-05-22 Wyeth 4-Anilino-3-quinolinecarbonitriles for the treatment of acute myelogenous leukemia (AML)
WO2008089135A2 (en) * 2007-01-12 2008-07-24 University Of South Florida Identification of biomarkers predictive of dasatinib effects in cancer cells
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
WO2009076373A1 (en) * 2007-12-10 2009-06-18 Concert Pharmaceuticals Inc. Heterocyclic kinase inhibitors
KR101922096B1 (ko) 2008-06-17 2018-11-27 와이어쓰 엘엘씨 Ｈｋｉ-272 및 비노렐빈을 함유하는 항신생물성 조합물
US8119129B2 (en) * 2008-08-01 2012-02-21 Bristol-Myers Squibb Company Combination of anti-CTLA4 antibody with dasatinib for the treatment of proliferative diseases
PL2326329T3 (pl) * 2008-08-04 2017-07-31 Wyeth Llc Przeciwnowotworowe połączenia 4-anilino-3-cyjanochinolin i kapecytabiny
WO2010077894A2 (en) * 2008-12-16 2010-07-08 Bristol-Myers Squibb Company Methods of inhibiting quiescent tumor proliferation
EP3659596A1 (en) * 2009-07-20 2020-06-03 Bristol-Myers Squibb Company Combination of anti-ctla4 antibody with paclitaxel for the synergistic treatment of proliferative diseases
AU2010302961A1 (en) * 2009-10-01 2012-04-19 Csl Limited Method of treatment of philadelphia chromosome positive leukaemia

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6011029A (en) * 1996-02-26 2000-01-04 Bristol-Myers Squibb Company Inhibitors of farnesyl protein transferase
US7125875B2 (en) * 1999-04-15 2006-10-24 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
CN1348370A (zh) * 1999-04-15 2002-05-08 布里斯托尔-迈尔斯斯奎布公司 环状蛋白酪氨酸激酶抑制剂
TWI310684B (en) * 2000-03-27 2009-06-11 Bristol Myers Squibb Co Synergistic pharmaceutical kits for treating cancer
NZ529145A (en) * 2001-05-16 2005-07-29 Novartis Ag Combination comprising N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)- 2pyrimidine-amine and a chemotherapeutic agent
WO2004015130A2 (en) * 2002-08-07 2004-02-19 Exelixis Modulators of rabggt and methods of use thereof
US20050009891A1 (en) * 2003-07-09 2005-01-13 Lee Francis Y. Combination of SRC Kinase inhibitors and chemotherapeutic agents for the treatment of proliferative diseases
MY144177A (en) * 2004-02-04 2011-08-15 Novartis Ag Salt forms of 4-(4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide.
US7491725B2 (en) * 2004-02-06 2009-02-17 Bristol-Myers Squibb Company Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors
TW200628156A (en) * 2004-11-04 2006-08-16 Bristol Myers Squibb Co Combination of a SRC kinase inhibitor and a BCR-ABL inhibitor for the treatment of proliferative diseases

Also Published As

Publication number Publication date
TW200722091A (en) 2007-06-16
US20060235006A1 (en) 2006-10-19
WO2006113304A3 (en) 2007-08-02
US20090054415A1 (en) 2009-02-26
MX2007012537A (es) 2007-12-10
WO2006113304A2 (en) 2006-10-26
EP1868435A4 (en) 2009-04-01
AU2006236812A1 (en) 2006-10-26
CA2604581A1 (en) 2006-10-26
KR20080004495A (ko) 2008-01-09
JP2008536853A (ja) 2008-09-11
EA200702238A1 (ru) 2008-04-28
BRPI0608176A2 (pt) 2009-11-17
EP1868435A2 (en) 2007-12-26

Similar Documents

Publication Publication Date Title
NO20075087L (no) Kombinasjoner, metoder og sammensetninger for behandling av cancer
GEP20104927B (en) Formulations of a src/abl inhibitor
TW200700416A (en) 'n-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamides metabolites
NO20076554L (no) Pyrimidin- eller triazinkondenserte, bisykliske metalloproteaseinhibitorer
EA200800727A1 (ru) Введение ингибиторов дипептидилпептидазы
CY1111086T1 (el) Παραγωγα 2-αμινο-κιναζολινης χρησιμα ως αναστολεις της βητα-σεκρετασης (bace)
IL194744A (en) Derivatives 1– (alkyl) –3– (amino-converted) –5– (converted) - s-triazole, a process for their preparation and pharmacological preparations containing them for the treatment of psychotic diseases
NO20070526L (no) Kinazolindionderivater som parp-inhibitorer
DK1567488T3 (da) Hydroxyethylaminderivater til behandling af Alzheimers sygdom
DE60314013D1 (de) 2-(1h-indazol-6-ylamino)- benzamid-verbindungen als protein kinase inhibitoren und deren verwendung zur behandlung von ophthalmischen krankheiten
NO20071549L (no) Nye benzofuserte heteroalrylsulfamidderivater, anvendelige som anti-krampemidler
SV2002000287A (es) Uso de inhibidor de la quinasa dependiente de la ciclina para preparar una composicion farmaceutica util para tratar enfermedades neurodegenerativas
ATE536353T1 (de) 2-(4-amino-1,2,5-oxadiazol-4-yl)-imidazol- verbindungen als protein kinase inhibitoren
NO20092412L (no) Hydantoinderivater anvendes som MMP-inhibitorer
NO20072567L (no) Triazoler nyttige som proteinkinase-inhibitorer
ATE522526T1 (de) 4-(3-(2-(phenyl)morpholino)-2-oxopyrrolidin-1-y )-n-(thiazol-2-yl)benzolsulfonamidderivate und verwandte verbindungen als ionenkanalmodulatoren zur behandlung von schmerzen
MX2010002938A (es) Derivados de (3-hidroxi-4-amino-butan-2-il)-3-(2-tiazol-2-il-pirro lidin-1-carbonil)benzamida y compuestos relacionados como inhibidores de beta-secretasa para tratar enfermedad de alzheimer.
DK1789398T3 (da) 2-amino-quinazolin derivater anvendelige som inhibitorer af B-sekretase (BACE)
NO20073571L (no) Nye hydantoinderivater som metallproteinaseinhibitorer
ATE423105T1 (de) Triazolonderivate als mmp-inhibitoren zur behandlung von asthma und copd
MX2009003974A (es) N-(2-hidroxietil)-n-metil-4-(quinolin-8-il(1-(tiazol-4-ilmetil)pi peridin-4-ilideno)metil)benzamida, el proceso para su sintesis, asi como su uso para el tratamiento del dolor, la ansiedad y la depresion.
NO20062022L (no) 1-(kinolinamino)- og 1-(isokinolinamino)-substituerte pentan-2-oler, fremgangsmate for fremstilling av disse og anvendelse av den som antiinflammatoriske midler
BRPI0614481A2 (pt) composto, composição farmecêutica, uso do composto, e, método de tratamento de distúrbios mediados por mglur5
SE0402284D0 (sv) New heterocyclic amides
UY29165A1 (es) Nuevo procedimiento y compuestos intermedios de preparación de derivados de n-(1-benzhidril-azetidin-3-il)-n-fenil-metilsulfonamida.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application